Epstein-Barr Virus-Associated Secondary Hemophagocytic Syndrome and Chronic Active Disease: A Literature Review

Epstein-Barr virus (EBV) infection can cause secondary hemophagocytic syndrome and severe chronic active disease. The diseases are characterized by pathologic hyperergic reaction manifested by fever, cytopenia, and multiple organ failure. Cytostatic therapy reduces inflammatory response, allows for infection resolution, or stabilizes the patient before the next stage of treatment. This paper reviews current knowledge about diagnosis and treatment of EBV-associated diseases with the main focus on chemotherapy for EBV-associated secondary hemophagocytic syndrome and chronic active disease.

• Vsevolod Gennadevich Potapenko City Clinical Hospital No. 31, 3 Dinamo pr-t, Saint Petersburg, Russian Federation, 197110 https://orcid.org/0000-0003-2985-0503 (unauthenticated)
• M.M. Antonov SP Botkin Clinical Hospital for Infectious Diseases, 3 Mirgorodskaya ul., Saint Petersburg, Russian Federation, 191167 https://orcid.org/0009-0009-6664-9228 (unauthenticated)

1. Пиневич А.В., Сироткин А.К., Гаврилова О.В., Потехин А.А. Вирусология: учебник. СПб.: Издательство Санкт-Петербургского университета, 2012. 320 с. [Pinevich A.V., Sirotkin A.K., Gavrilova O.V., Potekhin A.A. Virusologiya: uchebnik. (Virology: textbook.) Saint Petersburg: Izdatelstvo Sankt-Peterburgskogo Universiteta Publ.; 2012. 320 p. (In Russ)]
2. Evans AS, Niederman JC, Cenabre LC, et al. A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody. J Infect Dis. 1975;132(5):546–54. doi: 10.1093/infdis/132.5.546. DOI: https://doi.org/10.1093/infdis/132.5.546
3. Linderholm M, Boman J, Juto P, Linde A. Comparative evaluation of nine kits for rapid diagnosis of infectious mononucleosis and Epstein-Barr virus-specific serology. J Clin Microbiol. 1994;32(1):259–61. doi: 10.1128/jcm.32.1.259-261.1994. DOI: https://doi.org/10.1128/jcm.32.1.259-261.1994
4. Schooley RT. Epstein-Barr virus (infectious mononucleosis). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2000. рр. 1599–613.
5. Geramizadeh B, Aghdai M, Azarpira N, et al. Incidence of reactive antibodies against Epstein-Barr in a group of renal transplant patients. Transplant Proc. 2005;37(7):3051–2. doi: 10.1016/j.transproceed.2005.08.068. DOI: https://doi.org/10.1016/j.transproceed.2005.08.068
6. De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol. 2012;1(1):31–43. doi: 10.5501/wjv.v1.i1.31. DOI: https://doi.org/10.5501/wjv.v1.i1.31
7. Калугина М.Ю., Бошьян Р.Е., Каражас Н.В. и др. Маркеры вируса герпеса 6-го типа, цитомегаловируса и вируса Эпштейна-Барр у больных гемобластозами. Клиническая лабораторная диагностика. 2007;9:71. [Kalugina M.Yu., Boshyan R.E., Karazhas N.V., et al. Markers of herpes virus type 6, cytomegalovirus and Epstein-Barr virus in patients with hematological malignancies. Klinicheskaya laboratornaya diagnostika. 2007;9:71. (In Russ)]
8. Корниенко М.Н., Рыбалкина Т.Н., Каражас Н.В. и др. Выявление маркеров оппортунистических инфекций и вирусных гепатитов у онкогематологических пациентов. Эпидемиология и инфекционные болезни. 2015;6:33–8. [Kornienko M.N., Rybalkina T.N., Karazhas N.V., et al. Identification of markers of opportunistic infections and viral hepatitis in oncohematological patients. Epidemiologiya i infektsionnye bolezni. 2015;6:33–8. (In Russ)] DOI: https://doi.org/10.17816/EID40888
9. Lupo J, Germi R, Lancar R, et al. Prospective evaluation of blood Epstein-Barr virus DNA load and antibody profile in HIV-related non-Hodgkin lymphomas. AIDS. 2021;35(6):861–8. doi: 10.1097/QAD.0000000000002839. DOI: https://doi.org/10.1097/QAD.0000000000002839
10. Lupo J, Germi R, Lancar R, et al. Epstein-Barr virus biomarkers have no prognostic value in HIV-related Hodgkin lymphoma in the modern combined antiretroviral therapy era. AIDS. 2019;33(6):993–1000. doi: 10.1097/QAD.0000000000002129. DOI: https://doi.org/10.1097/QAD.0000000000002129
11. Enblad G, Sandvej K, Lennette E, et al. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin’s disease. Int J Cancer. 1997;72(3):394–7. doi: 10.1002/(sici)1097-0215(19970729)72:3<394::aid-ijc3>3.0.co;2-k. DOI: https://doi.org/10.1002/(SICI)1097-0215(19970729)72:3<394::AID-IJC3>3.3.CO;2-0
12. Ziarkiewicz M, Wolosz D, Dzieciatkowski T, et al. Epstein-Barr Virus-Positive Diffuse Large B cell Lymphoma in the Experience of a Tertiary Medical Center in Poland. Arch Immunol Ther Exp (Warsz). 2016;64(2):159–69. doi: 10.1007/s00005-015-0341-2. DOI: https://doi.org/10.1007/s00005-015-0341-2
13. Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn. 2004;6(4):378–85. doi: 10.1016/S1525-1578(10)60535-1. DOI: https://doi.org/10.1016/S1525-1578(10)60535-1
14. Geçgel KS, Ersoy A, Sevinir BB, et al. Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections. Mikrobiyol Bul. 2012;46(4):594–606.
15. Fouquet G, Larroche C, Carpentier B, et al. Splenectomy for haemophagocytic lymphohistiocytosis of unknown origin: risks and benefits in 21 patients. Br J Haematol. 2021;194(3):638–42. doi: 10.1111/bjh.17497. DOI: https://doi.org/10.1111/bjh.17497
16. Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci. 2003;10(5):490–504. doi: 10.1007/BF02256110. DOI: https://doi.org/10.1007/BF02256110
17. Hamilton-Dutoit SJ, Pallesen G. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization. Histopathology. 1994;25(2):101–11. doi: 10.1111/j.1365-2559.1994.tb01565.x. DOI: https://doi.org/10.1111/j.1365-2559.1994.tb01565.x
18. Qi ZL, Han XQ, Hu J, et al. Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin’s lymphoma in paraffin-embedded tissues. Mol Med Rep. 2013;7(1):89–92. doi: 10.3892/mmr.2012.1163. DOI: https://doi.org/10.3892/mmr.2012.1163
19. Ambinder RF, Mann RB. Epstein-Barr-encoded RNA in situ hybridization: diagnostic applications. Hum Pathol. 1994;25(6):602–5. doi: 10.1016/0046-8177(94)90227-5. DOI: https://doi.org/10.1016/0046-8177(94)90227-5
20. Gulley ML, Glaser SL, Craig FE, et al. Guidelines for interpreting EBER in situ hybridization and LMP-1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. Am J Clin Pathol. 2002;117(2):259–67. doi: 10.1309/MMAU-0QYH-7BHA-W8C2. DOI: https://doi.org/10.1309/MMAU-0QYH-7BHA-W8C2
21. Гаврилов А.В., Марунич Н.А., Фигурнов В.А. Инфекционный мононуклеоз: Учебное пособие. Благовещенск, 2015. [Gavrilov A.V., Marunich N.A., Figurnov V.A. Infektsionnyi mononukleoz: Uchebnoe posobie. (Infectious mononucleosis: textbook.) Blagoveshchensk; 2015. (In Russ)]
22. Tyring S, Moore AY, Lupi O. Mucocutaneous Manifestations of Viral Diseases: An Illustrated Guide to Diagnosis and Management. 2nd ed. CRC Press; 2016. рр. 123. DOI: https://doi.org/10.3109/9781420073133
23. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Elsevier Inc.; 2014.
24. Шувалова Е.П. Тропические болезни: Учебник. СПб., 2004. 703 с. [Shuvalova E.P. Tropicheskie bolezni: Uchebnik. (Tropical diseases: textbook.) Saint Petersburg; 2004. 703 p. (In Russ)]
25. Tynnell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis. 1996;174(2):324–31. doi: 10.1093/infdis/174.2.324. DOI: https://doi.org/10.1093/infdis/174.2.324
26. Hu H, Deng H, Bi J, et al. Clinical characteristics and effectiveness of antiviral agents in hospitalized children with infectious mononucleosis in China: A multicenter retrospective study. Pediatr Investig. 2021;5(3):188–94. doi: 10.1002/ped4.12294. DOI: https://doi.org/10.1002/ped4.12294
27. Zhu MH, Liang M, Wang ZJ, Wen HY. Value of antiviral therapy for infectious monocytosis in children. Zhongguo Dang Dai Er Ke Za Zhi. 2012;14(3):198–201.
28. Andersson J, Sköldenberg B, Henle W, et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection. 1987;15(Suppl 1):S14–20. doi: 10.1007/BF01650106. DOI: https://doi.org/10.1007/BF01650106
29. Масчан М.А. Молекулярно-генетическая диагностика и дифференцированная терапия гистиоцитарных пролиферативных заболеваний у детей: Автореф. дис. … д-ра мед. наук. М., 2011. 62 с. [Maschan M.A. Molekulyarno-geneticheskaya diagnostika i differentsirovannaya terapiya gistiotsitarnykh proliferativnykh zabolevanii u detei. (Molecular genetic diagnosis and differential therapy of histiocytic proliferative diseases in children.) [dissertation] Moscow; 2011. 62 p. (In Russ)]
30. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–16. doi: 10.1016/S0140-6736(13)61048-X. DOI: https://doi.org/10.1016/S0140-6736(13)61048-X
31. Yoon SE, Eun Y, Huh K, et al. A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. Ann Hematol. 2020;99(9):2095–104. doi: 10.1007/s00277-020-04083-6. DOI: https://doi.org/10.1007/s00277-020-04083-6
32. Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93–105. doi: 10.1002/rmv.638. DOI: https://doi.org/10.1002/rmv.638
33. Kelesidis T, Humphries R, Terashita D, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County. J Med Virol. 2012;84(5):777–85. doi: 10.1002/jmv.23267. DOI: https://doi.org/10.1002/jmv.23267
34. Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol. 2002;44(3):283–94. doi: 10.1016/s1040-8428(02)00119-1. DOI: https://doi.org/10.1016/S1040-8428(02)00119-1
35. Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–49. doi: 10.1182/blood-2010-11-316745. DOI: https://doi.org/10.1182/blood-2010-11-316745
36. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280–6. doi: 10.1182/blood.v98.2.280. DOI: https://doi.org/10.1182/blood.V98.2.280
37. Arico M, Danesino C, Pende D, Moretta L. Pathogenesis of haemophagocytic lymphohistiocytosis. Br J Haematol. 2001;114(4):761–9. doi: 10.1046/j.1365-2141.2001.02936.x. DOI: https://doi.org/10.1046/j.1365-2141.2001.02936.x
38. Первакова М.Ю., Потапенко В.Г., Ткаченко О.Ю. и др. Цитокиновые паттерны летальных гипервоспалительных состояний, индуцированных вторичным гемофагоцитарным синдромом, бактериальным сепсисом и COVID-19. Иммунология. 2022;43(2):174–87. doi: 10.33029/0206-4952-2022-43-2-174-187. [Pervakova M.Yu., Potapenko V.G., Tkachenko O.Yu., et al. Cytokine patterns of fatal hyperinflammatory conditions, caused by secondary hemophagocytic lymphohistiocytosis, bacterial sepsis and COVID-19. Immunologiya. 2022;43(2):174–87. doi: 10.33029/0206-4952-2022-43-2-174-187. (In Russ)] DOI: https://doi.org/10.33029/0206-4952-2022-43-2-174-187
39. Потапенко В.Г., Климович А.В., Первакова М.Ю. и др. Вторичный гемофагоцитарный синдром у взрослых больных. Анализ 91 наблюдения. Онкогематология. 2020;15(4):52–64. doi: 10.17650/1818-8346-2020-15-4-52-64. [Potapenko V.G., Klimovich A.V., Pervakova M.Yu., et al. Secondary hemophagocytic syndrome in adult patients. Study of 91 patients. Oncohematology. 2020;15(4):52–64. doi: 10.17650/1818-8346-2020-15-4-52-64. (In Russ)] DOI: https://doi.org/10.17650/1818-8346-2020-15-4-52-64
40. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31. doi: 10.1002/pbc.21039. DOI: https://doi.org/10.1002/pbc.21039
41. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a Score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20. doi: 10.1002/art.38690. DOI: https://doi.org/10.1002/art.38690
42. Janka GE, Lehmberg K. Hemophagocytic syndromes – an update. Blood Rev. 2014;28:135–42. doi: 10.1016/j.blre.2014.03.002. DOI: https://doi.org/10.1016/j.blre.2014.03.002
43. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer. 1979;44(3):993–1002. doi: 10.1002/1097-0142(197909)44:3<993::aid-cncr2820440329>3.0.co;2-5. DOI: https://doi.org/10.1002/1097-0142(197909)44:3<993::AID-CNCR2820440329>3.0.CO;2-5
44. Gars E, Purington N, Scott G, et al. Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis. Haematologica. 2018;103(10):1635–41. doi: 10.3324/haematol.2017.186627. DOI: https://doi.org/10.3324/haematol.2017.186627
45. Потапенко В.Г., Карпушин А.А., Леенман Е.Е. и др. Лихорадка, ассоциированная с металлоконструкцией: клиническое наблюдение. Журнал инфектологии. 2019;12(3):126–30. doi: 10.22625/2072-6732-2019-11-3-126-130. [Potapenko V.G., Karpushin A.A., Leenman E.E., et al. Fever associated with metal device. Case report. Journal Infectology. 2019;11(3):126–30. doi: 10.22625/2072-6732-2019-11-3-126-130. (In Russ)] DOI: https://doi.org/10.22625/2072-6732-2019-11-3-126-130
46. Шаркова В.Е., Власов Г.С., Свежова Н.В. Ошибки при проведении иммуноферментного анализа. Клиническая лабораторная диагностика. 2007;3:42–5. [Sharkova V.E., Vlasov G.S., Svezhova N.V. Errors in enzyme immunoassay. Klinicheskaya laboratornaya diagnostika. 2007;3:42–5. (In Russ)]
47. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:2–26. doi: 10.1016/j.coi.2017.08.004. DOI: https://doi.org/10.1016/j.coi.2017.08.004
48. Shaw TY, Schivo M. Weathering a Cytokine Storm: A Case of EBV-Induced Hemophagocytic Lymphohistiocytosis. J Investig Med High Impact Case Rep. 2016;4(2):2324709616647409. doi: 10.1177/2324709616647409. DOI: https://doi.org/10.1177/2324709616647409
49. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol. 2001;19(10):2665–73. doi: 10.1200/JCO.2001.19.10.2665. DOI: https://doi.org/10.1200/JCO.2001.19.10.2665
50. Fadeel B, Orrenius S, Henter JI. Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. Br J Haematol. 1999;106(2):406–15. doi: 10.1046/j.1365-2141.1999.01538.x. DOI: https://doi.org/10.1046/j.1365-2141.1999.01538.x
51. Kasibhatla S, Brunner T, Genestier L. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1(4):543–51. doi: 10.1016/s1097-2765(00)80054-4. DOI: https://doi.org/10.1016/S1097-2765(00)80054-4
52. Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84–91. doi: 10.4049/jimmunol.1302282. DOI: https://doi.org/10.4049/jimmunol.1302282
53. La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–77. doi: 10.1182/blood.2018894618. DOI: https://doi.org/10.1182/blood.2018894618
54. Goede JS, Peghini PE, Fehr J. Oral Low Dose Etoposide in the Treatment of Macrophage Activation Syndrome. Blood. 2004;104(11):3817. doi: 10.1182/blood.V104.11.3817.3817. DOI: https://doi.org/10.1182/blood.V104.11.3817.3817
55. Этопозид (инструкция по медицинскому применению) препарата. Доступно по: https://www.vidal.ru/drugs/etoposide__12824?ysclid=m208xz6z1f697899553. Ссылка активна на 18.05.2025. [Etoposide (package insert). Available from: https://www.vidal.ru/drugs/etoposide__12824?ysclid=m208xz6z1f697899553. Accessed 18.05.2025. (In Russ)]
56. Wei A, Ma H, Li Z, et al. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Int J Hematol. 2020;112(4):568–76. doi: 10.1007/s12185-020-02936-4. DOI: https://doi.org/10.1007/s12185-020-02936-4
57. Cheng CN, Chu WY, Chang KC, Chen JS. Lymphoma-based therapy for refractory or relapsed Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in children. J Formos Med Assoc. 2022;121(11):2351–5. doi: 10.1016/j.jfma.2022.01.009. DOI: https://doi.org/10.1016/j.jfma.2022.01.009
58. Wei A, Ma HH, Zhang LP, et al. Ruxolitinib combined with liposomal doxorubicin, etoposide, methylprednisolone +/– PEG-asparaginase in treatment of relapsed/refractory pediatric hemophagocytic lymphohistiocytosis. Zhonghua Yi Xue Za Zhi. 2022;102(28):2167–72. doi: 10.3760/cma.j.cn112137-20211224-02888.
59. Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9(1):84. doi: 10.1186/s13045-016-0317-7. DOI: https://doi.org/10.1186/s13045-016-0317-7
60. Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6(5):1508–17. doi: 10.1016/j.jaip.2018.05.031. DOI: https://doi.org/10.1016/j.jaip.2018.05.031
61. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140(11):1229–53. doi: 10.1182/blood.2022015851. DOI: https://doi.org/10.1182/blood.2022015851
62. Quintanilla-Martinez L, Ko Y-H, Kimura H, et al. EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood. In: Swerdlow SH, Campo E, Harris NL, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC Press; 2017. рр. 355–62.
63. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527–33. doi: 10.1086/367988. DOI: https://doi.org/10.1086/367988
64. Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol. 2005;80(1):64–9. doi: 10.1002/ajh.20398. DOI: https://doi.org/10.1002/ajh.20398
65. Kimura H, Ito Y, Kawabe S, et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood. 2012;119(3):673–86. doi: 10.1182/blood-2011-10-381921. DOI: https://doi.org/10.1182/blood-2011-10-381921
66. Kimura H. Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16(4):251–61. doi: 10.1002/rmv.505. DOI: https://doi.org/10.1002/rmv.505
67. Kawada JI, Ito Y, Ohshima K, et al. Updated guidelines for chronic active Epstein-Barr virus disease. Int J Hematol. 2023;118(5):568–76. doi: 10.1007/s12185-023-03660-5. DOI: https://doi.org/10.1007/s12185-023-03660-5
68. Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18. doi: 10.1007/s12185-017-2192-6. DOI: https://doi.org/10.1007/s12185-017-2192-6
69. Du D, Li X, Wang L, et al. Chronic active Epstein-Barr virus infection mimicking dermatomyositis. Indian J Dermatol Venereol Leprol. 2023;89(1):94–9. doi: 10.25259/IJDVL_485_2021. DOI: https://doi.org/10.25259/IJDVL_485_2021
70. Ma Y, Zhang P, Bao Y, et al. Outcomes of programmed death protein-1 inhibitors treatment of chronic active Epstein Barr virus infection: A single center retrospective analysis. Front Immunol. 2023;14:1093719. doi: 10.3389/fimmu.2023.1093719. DOI: https://doi.org/10.3389/fimmu.2023.1093719
71. Onishi Y, Onodera K, Fukuhara N, et al. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders. Int J Hematol. 2022;115(6):873–81. doi: 10.1007/s12185-022-03313-z. DOI: https://doi.org/10.1007/s12185-022-03313-z
72. Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant. 2011;46(1):77–83. doi: 10.1038/bmt.2010.122. DOI: https://doi.org/10.1038/bmt.2010.122
73. Потапенко В.Г., Потихонова Н.А., Байков Б.В. и др. Вторичный гемофагоцитарный синдром у взрослых в клинической практике гематолога: обзор литературы и собственные данные. Клиническая онкогематология. 2015;8(2):169–84. doi: 10.21320/2500-2139-2015-8-2-169-184. [Potapenko V.G., Potikhonova N.A., Baikov V.V., et al. Secondary Hemophagocytic Syndrome in Adult Patients: Literature Review and Authors’ Experience. Clinical oncohematology. 2015;8(2):169–84. doi: 10.21320/2500-2139-2015-8-2-169-184. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2015-8-2-169-184
74. Потапенко В.Г., Первакова М.Ю., Лапин С.В. и др. Роль фракционного анализа ферритина в диагностике вторичного гемфагоцитарного синдрома. Клиническая лабораторная диагностика. 2018;63(1):21–7. [Potapenko V.G., Pervakova M.Yu., Lapin S.V., et al. The role of ferritin fraction analysis in the diagnosis of secondary hemophagocytic syndrome. Klinicheskaya laboratornaya diagnostika. 2018;63(1):21–7. (In Russ)]
75. Потапенко В.Г., Первакова М.Ю., Титов А.В. и др. Клинико-лабораторная характеристика и дифференциальная диагностика вторичного гемофагоцитарного синдрома и сепсиса. Клиническая онкогематология. 2019;12(3):329–37. doi: 10.21320/2500-2139-2019-12-3-329-337. [Potapenko V.G., Pervakova M.Yu., Titov A.V., et al. Clinical and Laboratory Characteristics and Differential Diagnosis between Secondary Hemophagocytic Syndrome and Sepsis. Clinical oncohematology. 2019;12(3):329–37. doi: 10.21320/2500-2139-2019-12-3-329-337. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2019-12-3-329-337
76. Потапенко В.Г., Климович А.В., Авдошина Д.Д. и др. Органные поражения при вторичном гемофагоцитарном синдроме у взрослых. Клиническая онкогематология. 2021;14(1):91–102. doi: 10.21320/2500-2139-2021-14-1-91-102. [Potapenko V.G., Klimovich A.V., Avdoshina D.D., et al. Organ Lesions in Adults with Secondary Hemophagocytic Syndrome. Clinical oncohematology. 2021;14(1):91–102. doi: 10.21320/2500-2139-2021-14-1-91-102. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2021-14-1-91-102
77. Потапенко В.Г., Байков В.В., Маркова А.Ю. и др. Болезнь Кикучи–Фуджимото: обзор литературы и четыре клинических наблюдения. Онкогематология 2022;17(4):48–59. doi: 10.17650/1818-8346-2022-17-4-48-59. [Potapenko V.G., Baykov V.V., Markova А.Yu., et al. Kikuchi–Fujimoto disease: literature review and report of four cases. Oncohematology. 2022;17(4):48–59. doi: 10.17650/1818-8346-2022-17-4-48-59. (In Russ)] DOI: https://doi.org/10.17650/1818-8346-2022-17-4-48-59
78. Потапенко В.Г., Антонов М.М., Виноградова Н.В. и др. Вторичный гемофагоцитарный синдром как осложнение висцерального лейшманиоза: клиническое наблюдение. Онкогематология 2022;17(3):89–97. doi: 10.17650/1818-8346-2022-17-3-89-97. [Potapenko V.G., Antonov M.M., Vinogradova N.V., et al. Hemophagocytic syndrome associated with leishmaniasis: case report. Oncohematology. 2022;17(3):89–97. doi: 10.17650/1818-8346-2022-17-3-89-97. (In Russ)] DOI: https://doi.org/10.17650/1818-8346-2022-17-3-89-97
79. Потапенко В.Г., Антонов М.М., Антипова А.С. и др. Лечение вторичного гемофагоцитарного синдрома. Гематология и трансфузиология. 2024;69(4):423–41. doi: 10.35754/0234-5730-2024-69-4-423-441. [Potapenko V.G., Antonov М.М., Antipova A.S., et al. Treatment of secondary hemophagocytic syndrome. Russian journal of hematology and transfusiology. 2024;69(4):423–41. doi: 10.35754/0234-5730-2024-69-4-423-441. (In Russ)] DOI: https://doi.org/10.35754/0234-5730-2024-69-4-423-441